Ann: Half Yearly Report and Accounts , page-3

Importantly, Rett Syndrome is no longer considered to be a neurodevelopmental disorder because experiments in a mouse model of Rett Syndrome in which the normal MECP2 gene was added back showed that the symptoms can actually be reversed. Experiments conducted at MIT with the n-terminal tripeptide of IGF-1 or IGF-1(1-3) – Glypromate, the parent compound of NNZ-2566 – also showed that symptoms can be partially reversed with therapy. Following on from the MIT experiments, a Phase I/II clinical trial of Increlex® (recombinant human IGF-1) has been initiated at Boston Children’s Hospital. That trial is being supported by the International Rett Syndrome Foundation and Autism Speaks. As recently announced, the International Rett Syndrome Foundation will also be supporting Neuren’s Phase II trial of NNZ-2566 in Rett Syndrome.